Roberts, Glore & Co’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Roberts, Glore & Co's NBIX Position: Q3 2026 in Review
Roberts, Glore & Co sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,317 shares — an estimated $222K sold.
Roberts, Glore & Co first reported a position in NBIX in Q1 2024 and held it in 6 quarters. The position peaked at $222K in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Roberts, Glore & Co reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
- Roberts, Glore & Co sold 1,317 Neurocrine Biosciences shares in Q3 2026, an estimated $222K.
- Roberts, Glore & Co first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 6 quarters.
- Roberts, Glore & Co's Neurocrine Biosciences position peaked at $222K in Q2 2026.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Roberts, Glore & Co's 13F filing for Q3 2026, filed 13 Nov 2026.